| Title |
Effect of acetazolamide for long-lasting paroxysmal dystonia in a patient with multiple sclerosis: a case report and review of literature
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, April 2013
|
| DOI | 10.2147/ndt.s43688 |
| Pubmed ID | |
| Authors |
Pei-Chun Hsieh, Shu-Min Chen, Yao-Hong Guo, Ta-Shen Kuan, Wei-Jang Yen, Wen-Chen Chang, Yu-Ching Lin |
| Abstract |
Dystonia is a rare manifestation of multiple sclerosis (MS), but it always interferes with the functional performance and quality of life. We report a rare case of long-lasting paroxysmal dystonia associated with MS. The patient was a 40-year-old woman with relapsing- remitting MS for 6 years. During the latest attack of MS, she suffered from long-lasting paroxysmal dystonia in her left hand. Despite treatment with pulse high-dose intravenous methylprednisolone, interferon, and baclofen, along with occupational therapy, the dystonia persisted and significantly bothered her daily activities. Finally, she was treated with oral acetazolamide (250 mg, three times a day for 4 days), which was very effective for the control of her dystonia. The dystonic movement subsided without recurrence in a follow-up of 17 months. We advocate this effective and safe treatment for patients with paroxysmal dystonia associated with MS. |
Mendeley readers
The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 3% |
| Unknown | 35 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 10 | 28% |
| Student > Ph. D. Student | 5 | 14% |
| Other | 4 | 11% |
| Student > Doctoral Student | 2 | 6% |
| Student > Master | 2 | 6% |
| Other | 5 | 14% |
| Unknown | 8 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 28% |
| Neuroscience | 6 | 17% |
| Nursing and Health Professions | 5 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
| Agricultural and Biological Sciences | 2 | 6% |
| Other | 2 | 6% |
| Unknown | 9 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 December 2022.
All research outputs
#5,454,446
of 25,784,004 outputs
Outputs from Neuropsychiatric Disease and Treatment
#758
of 3,148 outputs
Outputs of similar age
#44,175
of 213,974 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#10
of 49 outputs
Altmetric has tracked 25,784,004 research outputs across all sources so far. Compared to these this one has done well and is in the 78th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,148 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 213,974 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.